Clinical Trials Arena on MSN
Acesion begins patient enrolment in AP31969 Phase II AF study
The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.
SAN DIEGO, Jan. 6, 2026 /PRNewswire/ — HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback